Victory Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Victory Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8,037	Closed	-$238K	–	2599
2022 Q4	$238K	Sell	8,037 -27,820	-78%	-$746K	﹤0.01%	2230
2022 Q3	$834K	Buy	35,857 +2,445	+7%	+$58.2K	﹤0.01%	1813
2022 Q2	$561K	Sell	33,412 -518,003	-94%	-$10.9M	﹤0.01%	2001
2022 Q1	$23.5M	Sell	551,415 -17,153	-3%	-$801K	0.02%	826
2021 Q4	$34.6M	Buy	568,568 +414,845	+270%	+$22.9M	0.03%	704
2021 Q3	$6.39M	Sell	153,723 -16,652	-10%	-$582K	0.01%	1255
2021 Q2	$5.17M	Sell	170,375 -9,617	-5%	-$291K	0.01%	1326
2021 Q1	$5.38M	Buy	179,992 +10,742	+6%	+$277K	0.01%	1315
2020 Q4	$3.04M	Buy	169,250 +17,520	+12%	+$338K	﹤0.01%	1380
2020 Q3	$2.89M	Sell	151,730 -55,853	-27%	-$987K	﹤0.01%	1327
2020 Q2	$3.23M	Sell	207,583 -231,885	-53%	-$3.56M	﹤0.01%	1280
2020 Q1	$6.43M	Buy	439,468 +303,972	+224%	+$3.87M	0.01%	1201
2019 Q4	$1.28M	Sell	135,496 -4,000	-3%	-$36.2K	﹤0.01%	1670
2019 Q3	$1.59M	Hold	139,496	–	–	﹤0.01%	1547
2019 Q2	$1.4M	Buy	+139,496	New	+$1.68M	﹤0.01%	1229

Other funds holding BCYC

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Victory Capital Management's BCYC Position: Q1 2023 in Review

Victory Capital Management sold out of Bicycle Therapeutics (BCYC) in Q1 2023, closing a stake of 8,037 shares — an estimated $238K sold.

Victory Capital Management first reported a position in BCYC in Q2 2019 and held it in 15 quarters. The position peaked at $34.6M in Q4 2021. 89 funds tracked by Wall St. Rank hold BCYC as of Q1 2023.

Victory Capital Management reported no remaining Bicycle Therapeutics position as of Q1 2023 after selling out during the quarter.
Victory Capital Management sold 8,037 Bicycle Therapeutics shares in Q1 2023, an estimated $238K.
Victory Capital Management first reported a position in Bicycle Therapeutics in Q2 2019 and held it in 15 quarters.
Victory Capital Management's Bicycle Therapeutics position peaked at $34.6M in Q4 2021.
89 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2023.

Based on Victory Capital Management's 13F filing for Q1 2023, filed 2 May 2023.